Takeda sweetens $60 billion Shire pitch as rival bows out

Rare disease specialist Shire says it is willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company this year. Silvia Antonioli reports......»»

Takeda made a fifth takeover proposal for rival drugmaker Shire, a last-ditch move by the Japanese company that would likely value the rare-drug specialist at more than $60 billion......»»

TOKYO/LONDON (Reuters) - Japan's Takeda Pharmaceutical nudged up its offer for Shire to 44.3 billion pounds ($62 billion) on Friday to try to persuade the rare-disease drugs specialist into talks after it rejected three previous proposals......»»

Japan’s Takeda said it had made a sweetened proposal to buy Shire after its three previous bids for the rival drugmaker that has drawn broader interest across the sector were rejected......»»

Japan’s Takeda said it had made a sweetened proposal to buy Shire, just a day after it had a bid rejected for the rival drugmaker that has drawn broader interest across the sector......»»

A potential bidding war for drugmaker Shire erupted after Japan’s Takeda said it made a $60 billion takeover offer and U.S. rival Allergan said it was considering making its own bid......»»

Japan’s Takeda said it has made a $60 billion takeover offer for Shire, a bid it said its Dublin-headquartered rival has rejected. Takeda said talks were continuing......»»

Japanese drugmaker Takeda has reached a $62 billion deal to buy rival Shire in the world's biggest takeover so far this year......»»

Takeda Pharmaceutical Co. on Tuesday reached an agreement to buy Shire PLC, capping a monthslong battle for control of the European drugmaker.....»»

Takeda Pharmaceutical agrees to buy London-listed Shire for 45.3 billion pounds ($61.50 billion) after the Japanese company raises the amount of cash in its offer to secure a recommendation. Silvia Antonioli reports......»»

Takeda Pharmaceutical agrees to buy London-listed Shire for 45.3 billion pounds ($61.5.....»»

The 240-year old biopharma company reinforced its global ambition in 2019 with the $62 billion acquisition of pharma firm Shire Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber speaks during a press confere.....»»

Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters......»»

Takeda Pharmaceutical Co Ltd agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of Britain's Shire......»»

The transaction could result in a multinotch downgrade on Takeda's A1 rating, Moody's Investors Service wrote in a report on Wednesday.....»»

Takeda is near a deal worth more than $60 billion to buy European drugmaker Shire, having raised its bid four times in a sign of how ardently Japan’s legacy companies are pursuing growth abroad as sales at home slow......»»

Japanese drugmaker Takeda has reached a tentative agreement to buy Ireland-based Shire for 46 billion pounds......»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on April 24) read more.....»»

LONDON/N.....»»

Takeda moved closer to securing a $64 billion takeover of Shire after the target said it was willing to recommend that shareholders accept the Japanese firm’s latest proposal......»»